Inhibrx Inc logo

Inhibrx Inc

$ 25.80 +0.72 (+2.87%) 11:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 1.12B
Enterprise V:
$ 1.15B
Volume:
377.08K
Avg Vol (2M):
451.60K
Volume:
377.08K
Market Cap $:
1.12B
PE Ratio:
At Loss
Avg Vol (2-Month):
451.60K
Enterprise Value $:
1.15B
PB Ratio:
0

Business Description

Description
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Name Current Vs Industry Vs History
Cash-To-Debt 0.83
Equity-to-Asset -0.21
Debt-to-Equity -5.03
Debt-to-EBITDA -1.58
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.74
Distress
Grey
Safe
Beneish M-Score -0.16
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 58.69
9-Day RSI 55.44
14-Day RSI 52.4
6-1 Month Momentum % 26.98
12-1 Month Momentum % -10.38

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.05
Quick Ratio 6.05
Cash Ratio 5.75
Days Sales Outstanding 37.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.9

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -2384.41
Net Margin % -2647.68
ROE % -923.32
ROA % -78.55
ROIC % -721.42
ROC (Joel Greenblatt) % -1263.96
ROCE % -82.87